Lantern Pharma Inc.

NasdaqCM:LTRN Stock Report

Market Cap: US$35.2m

Lantern Pharma Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Panna Sharma

Chief executive officer

US$763.8k

Total compensation

CEO salary percentage75.29%
CEO tenure7.8yrs
CEO ownershipn/a
Management average tenure7.1yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

Analysis Article • Nov 21

Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 21

Will Lantern Pharma (NASDAQ:LTRN) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Nov 05

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 12

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Feb 28

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 06

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jul 20

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 04

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Dec 19

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 02

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 14

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Lantern Pharma (NASDAQ:LTRN) said the U.S. Food and Drug Administration (FDA) cleared the company to proceed with a phase 2 trial of LP-300 for never smoker patients with advanced non-small cell lung cancer (NSCLC). The study, dubbed Harmonic, will include 90 patients of which about 2/3 patients will receive LP-300 in combination with chemotherapy, while 1/3rd will receive chemotherapy alone. The company expects enrollment to occur over the next 12 to 16 months across multiple sites in the U.S. The company noted that in a previous phase 3 study, a subset of never smoker patients with NSCLC receiving LP-300 with chemotherapy showed increased overall and two-year survival of 91% and 125%, respectively, compared to patients on chemotherapy alone. LTRN +2.88% to $6.08 premarket July 14
Analysis Article • May 20

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 02

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 13

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 24

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Lantern is This has proven to be an unpopular sector of biotech across the past 12 months, with a lack of tangible progress causing share prices of most companies to fall. Lantern has 2 clinical opportunities in never-smokers with NSCLC and Prostate cancer, and significant funds with which to fund trials and potentially in-license more assets. The company hopes to create a powerful drug development platform in RADR, its data store, but realistically a decade's more data may be required to generate meaningful insight. Near-term price catalysts seem to lack real promise, but you can never rule out a sudden breakthrough. Lantern could also interest investors with a long-term time frame looking for drug development exposure.
Analysis Article • May 05

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 19

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Every investor in Lantern Pharma Inc. ( NASDAQ:LTRN ) should be aware of the most powerful shareholder groups. Large...

CEO Compensation Analysis

How has Panna Sharma's remuneration changed compared to Lantern Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$764kUS$575k

-US$17m

Sep 30 2025n/an/a

-US$19m

Jun 30 2025n/an/a

-US$19m

Mar 31 2025n/an/a

-US$20m

Dec 31 2024US$1mUS$575k

-US$21m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$684kUS$525k

-US$16m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$475k

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$622kUS$432k

-US$12m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$2mUS$384k

-US$6m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$332kUS$267k

-US$2m

Compensation vs Market: Panna's total compensation ($USD763.75K) is about average for companies of similar size in the US market ($USD647.55K).

Compensation vs Earnings: Panna's compensation has been consistent with company performance over the past year.

CEO

Panna Sharma (54 yo)

7.8yrs
Tenure
US$763,750
Compensation

Mr. Panna L. Sharma, served as the Chief Executive Officer and President of Cancer Genetics, Inc. from May 2010 to February 02, 2018. Mr. Sharma founded TSG Partners (also known as The Sharma Group) in 200...

Leadership Team

NamePositionTenureCompensationOwnership
Panna Sharma
President7.8yrsUS$763.75kno data
David Margrave
CFO & Secretary7.9yrsUS$585.58k0%
$ 0
Kishor Bhatia
Chief Scientific Officer & Scientific Consultant6.4yrsUS$244.42k0%
$ 0
Peter Nara
Co-Founder & Advisorno dataUS$794.00no data
Marc Chamberlain
Chief Medical Officer of Starlight Therapeutics2.3yrsno datano data
7.1yrs
Average Tenure
64yo
Average Age

Experienced Management: LTRN's management team is seasoned and experienced (7.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Panna Sharma
President7.8yrsUS$763.75kno data
Vijay Chandru
Independent Director6.6yrsUS$51.00k0%
$ 0
Maria Maccecchini
Independent Director3.9yrsUS$51.00k0%
$ 0
Donald Keyser
Independent Chairman8.3yrsUS$56.00k0.41%
$ 143.7k
Lee Schalop
Independent Directorless than a yearUS$36.23kno data
David Silberstein
Independent Director7.9yrsUS$46.00k0%
$ 0
7.2yrs
Average Tenure
71.5yo
Average Age

Experienced Board: LTRN's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 19:23
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lantern Pharma Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chad MesserLake Street Capital Markets, LLC
Ashok KumarThinkEquity LLC